New article by bioprocessing experts explores the challenge of bottlenecks on biologic production
Fluids Handling

New article by bioprocessing experts explores the challenge of bottlenecks on biologic production

Photo of Watson Marlow Watson Marlow Send an email 11/03/2021
215 2 minutes read
Listen to this article
  • Biologics bring the hope of a cure for some of the most prevalent diseases
  • Challenges remain in reducing the enormous costs and simplifying the intensive and complex production process
  • A new article sheds light on how the bioprocessing industry can help accelerate biologics production

The biologics manufacturing industry has seen rapid growth in recent years, but challenges remain to reap the rewards that biologics offer. Bioprocessing expert, Jim Sanford, shares his insights in a new article on how the industry may increase capacity, intensify processes, regulate equipment and procedures, and enhance product integrity to reduce bottlenecks and accelerate biologics production.

The new article was launched today by a global leader in fluid management technology, Watson-Marlow Fluid Technology Group (WMFTG), and is now available to download.

With life expectancies rising globally, the prevalence of chronic diseases is also increasing, especially in emerging markets like Asia-Pacific and Latin America. This is driving the growth of the biologics market. Critical players are already investing in these emerging markets but further investment is needed in Asia-Pacific, Latin America, Africa, South America, Eastern Europe and Russia.

Biosimilars are becoming more prominent, rising to meet the growing demands of these developing nations. Several established monoclonal antibodies and other biologics are approaching the end of their patents and deals by big pharma in China and India will offer almost identical medicines at significantly reduced prices to avoid competition. Learnings will be taken from the US and Western European markets and suppliers will need to ensure that they can meet the demand for their products wherever they are used.

Ivan Strekalovsky, a bioprocessing expert at BIOCAD, shares his thoughts on the additional complications of manufacturing biologics in this article. “Assuring the quality of biopharmaceuticals is more complicated than for small molecules as they are synthesised by living cells. A lot of work is needed to develop the manufacturing process – for instance, regulatory approval is required and any minor changes must be well documented and validated,” commented Ivan. “Quality assurance and biosafety will be paramount, increasing demand for sterile equipment and single-use technologies.”

Jim Sanford, Sector Manager, Biopharm at Watson-Marlow Fluid Technology Group, added, “Single-use technology is essential to the biologics market, offering a complete fluid pathway. There is a clear need to reduce bioburden and eliminate the risk of particulate and endotoxin presence within the drug product. In order for our products to be suitable for tomorrow’s bioprocess, WMFTG has been testing its fluid paths portfolio to meet these evolving quality and performance requirements.”

Find out more from these experts on the global rise of biologics and the bioprocessing challenges that must be overcome by downloading the new report.

Watson Marlow
Premium Package

Watson-Marlow Fluid Technology Solutions

About us

Watson-Marlow Fluid Technology Group (WMFTG) peristaltic tube and hose pumps meet requirements including: value for money; low cost of ownership; reliability and ease of maintenance to the food and beverage, chemical, pharmaceutical, mining and many other industries.

We demonstrate how pumps deliver significant process efficiencies over the lifetime of the equipment. Whether performing flavouring addition in food processing, chemical metering in water treatment or mineral recovery, we have a solution which can cut pump downtime and reduce costs through higher accuracy metering and transfer. WMFTG has dedicated application engineers available to help customers make the right pump and tubing choice from a range providing microlitres per minute to 80 cubic metres per hour flow rates.

The only part of the pump to come into contact with the product is the tube or hose. This means there are no seals or valves that can wear or fail. Replacing the tube or hose can be performed quickly and safely. Peristaltic pump benefits include:

Total fluid containment with no seals No ancillaries Handle viscous and abrasive slurries and sludge Self-priming capability Dry running without damage to the pump In addition to their range of positive displacement pumps, Watson-Marlow Fluid Technology Group has added PTFE-lined chemical and industrial hoses to their range. Aflex hoses are reinforced to withstand the most severe conditions and use.

Where we supply to

Europe, Africa, Asia, Australia, South America, North America

Industries we supply to

Automation, Chemicals, Consultants, Components Electronics, Energy and Power, Food and Beverage, Glass Ceramics Cement, Metals and Minerals, OEM, Paper and Pulp, Pharmaceutical Cosmetics Toiletries, Plastics and Rubber, Recycling, Textiles, Tobacco, Water and Wastewater

  • Flexicon PF7 tabletop peristaltic liquid filling machine

  • Sterile ReNu SU Technology cartridge

  • Quantum and ReNu SU Technology cartridge - Make sterile connections in non-sterile environments

Photo of Watson Marlow Watson Marlow Send an email 11/03/2021
215 2 minutes read
Show More

    Would you like further information about this article?

    Add your details below and we'll be in touch ASAP!


    Input this code: captcha

    Back to top button
    PII logo

    Read our latest issue here

    Join 25,000 process industry specialists and subscribe to:

    • Process Industry Informer bi-monthly magazine
    • Process Industry Update weekly E-newsletter
    • And our regular Podcast and Webinars
    Yes, Sign Me Up!

    PII has a global network of suppliers ready to help...